Coherus Biosciences | CHRS - Ebitda


Coherus Biosciences reported $-43.33M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 100.31M 21.24M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
Baxter International USD 426M 36M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Fujifilm JPY 132.72B 8.92B Dec/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Myriad Genetics USD 14.3M 4M Dec/2025
Pacira USD 38.71M 10.65M Dec/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xencor USD -51.05M 55.28M Dec/2025
Zoetis USD 1.04B 87M Sep/2025